Cutaneous S100-negative, CD1a-positive histiocytosis successfully treated with combination therapy of oral methotrexate and corticosteroid

J Dermatol. 2015 Oct;42(10):999-1001. doi: 10.1111/1346-8138.12944. Epub 2015 May 28.

Abstract

S100-negative, CD1a-positive histiocytosis is a rare histiocytic disorder characterized by proliferation of histiocytic cells possessing a phenotype of epidermal Langerhans cells except for the lack of S100 expression and Birbeck granules. We report the case of a Japanese man suffering from S100-negative, CD1a-positive histiocytosis. The patient showed numerous smooth erythematous 5-10-mm papules/nodules on most of his body. The key histopathological feature was the presence of dermal infiltrates of non-epidermotropic S100-negative CD1a-positive mononuclear cells. No systemic involvement was detected. Initially bath-psoralen plus ultraviolet A therapy was effective, but the lesions became recalcitrant to this treatment. Methylprednisolone pulse therapy followed by low-dose methotrexate (up to 30 mg/week) in combination with prednisolone (15 mg/day) effectively controlled the skin lesions.

Keywords: CD1a; S100 protein; corticosteroid; histiocytosis; methotrexate; ultraviolet therapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antigens, CD1 / metabolism
  • Dermatologic Agents / therapeutic use*
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use*
  • Histiocytosis / drug therapy*
  • Histiocytosis / immunology
  • Humans
  • Male
  • Methotrexate / therapeutic use*
  • Prednisolone / therapeutic use*
  • S100 Proteins

Substances

  • Antigens, CD1
  • CD1a antigen
  • Dermatologic Agents
  • Glucocorticoids
  • S100 Proteins
  • Prednisolone
  • Methotrexate